| 阮 一,何 瑶,杨 啸,廖 玥,陈 肖.替格瑞洛对急性心肌梗死患者经皮冠状动脉介入治疗效果及血清CRP，cTnI，CK-MB水平的影响[J].,2017,17(33):6527-6530 |
| 替格瑞洛对急性心肌梗死患者经皮冠状动脉介入治疗效果及血清CRP，cTnI，CK-MB水平的影响 |
| Effects of Ticrolol on Percutaneous Coronary Intervention and Serum CRP, cTnI and CK-MB Levels in Patients with Acute Myocardial Infarction |
| 投稿时间：2017-06-17 修订日期：2017-07-12 |
| DOI：10.13241/j.cnki.pmb.2017.33.029 |
| 中文关键词: 替格瑞洛 心肌梗死 经皮冠状动脉介入术 C反应蛋白 心肌肌钙蛋白I 肌酸磷化脢-同功脢MB |
| 英文关键词: Tegrero Myocardial infarction Percutaneous coronary intervention C-reactive protein Cardiac troponin I Creatine phosphorylation-MB |
| 基金项目:重庆市自然科学基金项目（20125697013） |
|
| 摘要点击次数: 138 |
| 全文下载次数: 132 |
| 中文摘要: |
| 摘要 目的：探讨替格瑞洛对急性心肌梗死患者经皮冠状动脉介入治疗的效果及血清hs-CRP、cTnI、CK-MB水平与血小板功能的影响。方法：选择2015年7月至2016年7月我院接诊的86例急性心肌梗死患者，采取随机数表法分作观察组（n=43）与对照组（n=43）。对照组使用氯吡格雷治疗，观察组使用替格瑞洛治疗。比较两组心肌灌注分级(TMPG分级)、心肌梗塞溶栓治疗分级(TIMI分级)、C反应蛋白(CRP)、心肌肌钙蛋白I(cTnI)、肌酸磷化脢-同功脢MB(CK-MB)、血小板聚集率和不良心血管事件的发生率。结果：治疗后，观察组TMPG和TIMI分级均高于对照组(P<0.05)；观察组CRP、cTnI和CK-MB水平均低于对照组(P<0.05)；观察组血小板聚集率低于对照组(P<0.05)；观察组不良心血管事件发生率低于对照组(P<0.05)；观察组临床总有效率高于对照组(P<0.05)。结论：替格瑞洛能够有效改善急性心肌梗死行经皮冠状动脉介入治疗的患者冠脉血流灌注，降低血清CRP，cTnI和CK-MB水平，抑制血小板聚集，安全性较高，值得临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effects of ticrolol on percutaneous coronary intervention and serum hs-CRP, cTnI and CK-MB levels and platelet function in patients with acute myocardial infarction. Methods: 86 patients with acute myocardial infarction who re- ceived therapy from July 2015 to July 2016 in our hospital were selected as research objects. According to random number table method, the patients were divided into the observation group(n=43) and the control group(n=43). The control group was treated with clopidogrel and the observation group was treated with tirogreil. Then the myocardial perfusion grade (TMPG), myocardial infarction thrombolytic therapy grade (TIMI), C-reactive protein (CRP), cardiac troponin I (cTnI), CK-MB, platelet aggregation rate and adverse cardiovascular events were observed and compared. Results: After treatment, TMPG and TIMI of the observation group were higher than those of the control group(P<0.05). The levels of CRP, cTnI and CK-MB in the observation group were lower than those of the control group (P<0.05). The platelet aggregation rate in the observation group was lower than that of the control group(P<0.05). The incidence of adverse cardiovascular events in the observation group was lower than that of the control group(P<0.05). The total effective rate of the clinical group was higher than that of the control group (P<0.05). Conclusion: Tegrella can effectively improve the acute myocardial infarction in patients undergoing percutaneous coronary intervention in coronary artery blood flow perfusion, reduce serum CRP, cTnI and CK-MB levels, inhibition of platelet aggregation, and high safety, which is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
